1 results match your criteria: "Centre de Lutte Contre le Cancer du CHUM - Hôpital Notre-Dame[Affiliation]"
Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study.
Invest New Drugs
December 2013
Centre de Lutte Contre le Cancer du CHUM - Hôpital Notre-Dame, 6ième étage (G6162), Pavillon Deschamps, 1560 Sherbrooke Est, Montréal, QC, H2L 4M1, Canada,
Objectives: The maximum tolerated dose (MTD) and overall safety of sunitinib plus pemetrexed and carboplatin was determined in patients with advanced solid malignancies.
Methods: In this phase I dose-escalation study, patients received oral sunitinib on a continuous daily dosing (CDD) schedule (37.5 mg/day) or Schedule 2/1 (2 weeks on treatment, 1 week off treatment; 37.